María Dolores Ollero García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Dolores Ollero García has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Emma Anda
Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Navarra, Pamplona (Navarra), España; Instituto de Investigación Sanitaria de Navarra (IdisNa), Pamplona (Navarra), España
2 shared publicationsJavier Pineda
Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Navarra, Pamplona (Navarra), España; Instituto de Investigación Sanitaria de Navarra (IdisNa), Pamplona (Navarra), España
2 shared publicationsMarta Toni
Instituto de Investigación Sanitaria de Navarra (IdisNa), Pamplona (Navarra), España; Sección de Endocrinología, Hospital García Orcoyen, Estella (Navarra), España
2 shared publicationsMercedes Espada
Unidad de Química Clínica, Laboratorio de Salud Pública del Gobierno Vasco, Derio, España
2 shared publications- Aida Orois
Endocrinology and Nutrition Department , Hospital Clínic de Barcelona , Barcelona , Spain
1 shared publication - Alfonso Soto-Moreno
Unidad de Gestión de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 14004 Córdoba, Spain
1 shared publication
Latest Publications
- Open Access
- 25 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7575
Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.
- 25 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7575
Open AccessReal-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.
- 1 December 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (10) , 643-649
Evolución del estado de nutrición de yodo en gestantes del area sanitaria de Pamplona
- 1 December 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (10) , 643-649
Evolución del estado de nutrición de yodo en gestantes del area sanitaria de Pamplona
- 1 May 2019
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 66 (5) , 305-311
Optimización del seguimiento de gestantes con enfermedad tiroidea autoinmune
- 1 May 2019
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 66 (5) , 305-311
Optimización del seguimiento de gestantes con enfermedad tiroidea autoinmune